Kaijiong Zhang
Kaijiong Zhang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Bangrong Cao
Sichuan Key Laboratory of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China , Chengdu 610041
1 shared publication - Changchun Wu
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China
1 shared publication - Dongsheng Wang
Hebei University of Technology, Tianjin, China
1 shared publication - Dongsheng Wang
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
1 shared publication Gang Yin
Department of Clinical Laboratory, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610041, PR China
1 shared publicationHaimin Zou
Department of Clinical Laboratory, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610041, PR China
1 shared publication
Latest Publications
- Open Access
PlateletBase: A Comprehensive Knowledgebase for Platelet Research and Disease Insights
Platelets are vital in many pathophysiological processes, yet there is a lack of a comprehensive resource dedicated specifically to platelet research. To fill this gap, we have developed PlateletBase, a knowledge base aimed at enhancing the understanding and study of platelets and related diseases. Our team retrieved information from various public databases, specifically extracting and analyzing RNA-seq data from 3,711 samples across 41 different conditions available on NCBI. PlateletBase offers six analytical and visualization tools, enabling users to perform gene similarity analysis, pair correlation, multi-correlation, expression ranking, clinical information association, and gene annotation for platelets. The current version of PlateletBase includes 10,278 genomic entries, 31,758 transcriptomic entries, 4,869 proteomic entries, 2,614 omics knowledge entries, 1,833 drugs, 97 platelet resources, 438 diseases/traits, and six analysis modules. Each entry has been carefully curated and supported by experimental evidence. Additionally, PlateletBase features a user-friendly interface designed for efficient querying, manipulation, browsing, visualization, and analysis of detailed platelet protein and gene information. Case study results, such as those from gray platelet syndrome and angina pectoris, demonstrate that this tool can aid in identifying diagnostic biomarkers and exploring disease mechanisms, significantly advancing research in platelet functionality and its applications. PlateletBase is accessible at http://plateletbase.clinlabomics.org.cn/ .
Open AccessPlateletBase: A Comprehensive Knowledgebase for Platelet Research and Disease Insights
Platelets are vital in many pathophysiological processes, yet there is a lack of a comprehensive resource dedicated specifically to platelet research. To fill this gap, we have developed PlateletBase, a knowledge base aimed at enhancing the understanding and study of platelets and related diseases. Our team retrieved information from various public databases, specifically extracting and analyzing RNA-seq data from 3,711 samples across 41 different conditions available on NCBI. PlateletBase offers six analytical and visualization tools, enabling users to perform gene similarity analysis, pair correlation, multi-correlation, expression ranking, clinical information association, and gene annotation for platelets. The current version of PlateletBase includes 10,278 genomic entries, 31,758 transcriptomic entries, 4,869 proteomic entries, 2,614 omics knowledge entries, 1,833 drugs, 97 platelet resources, 438 diseases/traits, and six analysis modules. Each entry has been carefully curated and supported by experimental evidence. Additionally, PlateletBase features a user-friendly interface designed for efficient querying, manipulation, browsing, visualization, and analysis of detailed platelet protein and gene information. Case study results, such as those from gray platelet syndrome and angina pectoris, demonstrate that this tool can aid in identifying diagnostic biomarkers and exploring disease mechanisms, significantly advancing research in platelet functionality and its applications. PlateletBase is accessible at http://plateletbase.clinlabomics.org.cn/ .
- Open Access
- 1 November 2017
- Published by Wiley in Thoracic Cancer
- Vol. 9 (1) , 66-74
Detection and analysis of circulating large intergenic non‐coding RNA regulator of reprogramming in plasma for breast cancer
Background: Previous studies have indicated that large intergenic non‐coding RNA regulator of reprogramming (lincRNA‐ROR) plays an important role in regulating tumor carcinogenesis and metastasis; however, whether circulating lincRNA‐ROR could function as a potential biomarker for breast cancer (BC) diagnosis and monitoring is unknown. This study was conducted to investigate circulating lincRNA‐ROR in plasma as a potential biomarker for BC diagnosis and monitoring.Methods: We performed reverse transcription‐quantitative‐PCR to examine lincRNA‐ROR expression levels in cell lines, 24 pairs of BC tissue samples, and 94 plasma samples from BC patients. Potential correlations between plasma lincRNA‐ROR levels and clinicopathological characteristics were analyzed. A receiver operating characteristic curve was calculated to evaluate the diagnostic values for BC. Pearson correlation analysis of lincRNA‐ROR in plasma samples and the corresponding tissues of the same patients was performed to explore tumor monitoring values.Results: LincRNA‐ROR expression was significantly increased in BC cell lines, tissues, and plasma (all P < 0.01). Plasma lincRNA‐ROR levels were associated with estrogen receptors (P = 0.042) and lymph node metastasis (P = 0.046). The area under the receiver operating characteristic curve of plasma lincRNA‐ROR was 0.844 (sensitivity 80.0%, specificity 56.7%), which was higher than carcinoembryonic and carbohydrate antigen 15‐3 values. Moreover, plasma lincRNA‐ROR levels were decreased in postoperative compared to preoperative samples (P < 0.0001). Plasma lincRNA‐ROR levels moderately correlated with the corresponding tissue level in the same patients (r2 = 0.638, P < 0.0001).Conclusion: Plasma lincRNA‐ROR may be a potential biomarker for BC diagnosis and a dynamic monitor.
- 1 November 2017
- Published by Wiley in Thoracic Cancer
- Vol. 9 (1) , 66-74
Open AccessDetection and analysis of circulating large intergenic non‐coding RNA regulator of reprogramming in plasma for breast cancer
Background: Previous studies have indicated that large intergenic non‐coding RNA regulator of reprogramming (lincRNA‐ROR) plays an important role in regulating tumor carcinogenesis and metastasis; however, whether circulating lincRNA‐ROR could function as a potential biomarker for breast cancer (BC) diagnosis and monitoring is unknown. This study was conducted to investigate circulating lincRNA‐ROR in plasma as a potential biomarker for BC diagnosis and monitoring.Methods: We performed reverse transcription‐quantitative‐PCR to examine lincRNA‐ROR expression levels in cell lines, 24 pairs of BC tissue samples, and 94 plasma samples from BC patients. Potential correlations between plasma lincRNA‐ROR levels and clinicopathological characteristics were analyzed. A receiver operating characteristic curve was calculated to evaluate the diagnostic values for BC. Pearson correlation analysis of lincRNA‐ROR in plasma samples and the corresponding tissues of the same patients was performed to explore tumor monitoring values.Results: LincRNA‐ROR expression was significantly increased in BC cell lines, tissues, and plasma (all P < 0.01). Plasma lincRNA‐ROR levels were associated with estrogen receptors (P = 0.042) and lymph node metastasis (P = 0.046). The area under the receiver operating characteristic curve of plasma lincRNA‐ROR was 0.844 (sensitivity 80.0%, specificity 56.7%), which was higher than carcinoembryonic and carbohydrate antigen 15‐3 values. Moreover, plasma lincRNA‐ROR levels were decreased in postoperative compared to preoperative samples (P < 0.0001). Plasma lincRNA‐ROR levels moderately correlated with the corresponding tissue level in the same patients (r2 = 0.638, P < 0.0001).Conclusion: Plasma lincRNA‐ROR may be a potential biomarker for BC diagnosis and a dynamic monitor.